These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2193498)

  • 41. Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia.
    Igawa M; Aonuma K; Okamoto Y; Hiroe M; Hiraoka M; Isobe M
    J Cardiovasc Pharmacol; 2002 Nov; 40(5):735-42. PubMed ID: 12409982
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of successful suppression of sustained ventricular tachyarrhythmias by serial drug testing from data derived at the initial electrophysiologic study.
    Kuchar DL; Rottman J; Berger E; Freeman CS; Garan H; Ruskin JN
    J Am Coll Cardiol; 1988 Oct; 12(4):982-8. PubMed ID: 3047198
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lorcainide therapy for the high-risk patient post myocardial infarction.
    Somberg JC; Butler B; Torres V; Flowers D; Tepper D; Keefe D; Miura DS
    Am J Cardiol; 1984 Aug; 54(4):37B-42B. PubMed ID: 6465045
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
    Denes P; Gillis AM; Pawitan Y; Kammerling JM; Wilhelmsen L; Salerno DM
    Am J Cardiol; 1991 Oct; 68(9):887-96. PubMed ID: 1718158
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Propafenone for refractory ventricular arrhythmias: correlation with drug plasma levels during long-term treatment.
    Naccarella F; Bracchetti D; Palmieri M; Marchesini B; Ambrosioni E
    Am J Cardiol; 1984 Nov; 54(8):1008-14. PubMed ID: 6496321
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents.
    Kehoe RF; MacNeil DJ; Zheutlin TA; Ezri MD; Nazari J; Spangenberg RB; Dunnington C; Lueken M
    Am J Cardiol; 1993 Aug; 72(4):56A-66A. PubMed ID: 8346728
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Best Clinical Practice: Emergency Medicine Management of Stable Monomorphic Ventricular Tachycardia.
    Long B; Koyfman A
    J Emerg Med; 2017 Apr; 52(4):484-492. PubMed ID: 27751700
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hemodynamic effects of combined treatment with lignocaine, procainamide and practolol in acute myocardial infarction.
    Nordlander R; Nyquist O
    Cardiology; 1980; 66(1):27-42. PubMed ID: 7388852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mexiletine: double-blind comparison with procainamide in PVC suppression and open-label sequential comparison with amiodarone in life-threatening ventricular arrhythmias.
    Nademanee K; Feld G; Hendrickson J; Intarachot V; Yale C; Heng MK; Singh BN
    Am Heart J; 1985 Nov; 110(5):923-31. PubMed ID: 3904380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Procainamide: a perspective on its value and danger.
    Ellenbogen KA; Wood MA; Stambler BS
    Heart Dis Stroke; 1993; 2(6):473-6. PubMed ID: 8137053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Facilitation of ventricular tachycardia initiation by procainamide during programmed ventricular stimulation in patients with heart failure.
    Stevenson WG; Weiss J; Stevenson LW; Tillisch JH
    J Electrocardiol; 1990 Jan; 23(1):77-83. PubMed ID: 2406361
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Electropharmacologic testing in sustained ventricular tachycardia associated with coronary heart disease: value of the response to intravenous procainamide in predicting the response to oral procainamide and oral quinidine treatment.
    Oseran DS; Gang ES; Rosenthal ME; Mandel WJ; Peter T
    Am J Cardiol; 1985 Nov; 56(13):883-6. PubMed ID: 3904387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Usefulness of the response to intravenous procainamide during electrophysiologic study in predicting the response to oral quinidine in patients with inducible sustained monomorphic ventricular tachycardia associated with coronary artery disease.
    Pires LA; Wagshal AB; Greene TO; Mittleman RS; Huang SK
    Am J Cardiol; 1993 Oct; 72(12):908-10. PubMed ID: 8105674
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of incremental doses of procainamide on ventricular refractoriness, intraventricular conduction, and induction of ventricular tachycardia.
    Morady F; DiCarlo LA; de Buitleir M; Krol RB; Baerman JM; Kou WH
    Circulation; 1986 Dec; 74(6):1355-64. PubMed ID: 2430731
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of recurrent symptomatic ventricular tachycardia.
    Winkle RA; Alderman EL; Fitzgerald JW; Harrison DC
    Ann Intern Med; 1976 Jul; 85(1):1-7. PubMed ID: 937905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction.
    Campbell RW; Dolder MA; Prescott LF; Talbot RG; Murray A; Julian DG
    Lancet; 1975 Jun; 1(7919):1257-60. PubMed ID: 48894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiarrhythmic drug efficacy at electrophysiology testing: predictive effectiveness of procainamide and flecainide.
    Wynn J; Torres V; Flowers D; Mizruchi M; Keefe D; Miura D; Somberg J
    Am Heart J; 1986 Apr; 111(4):632-8. PubMed ID: 3953384
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug-induced narrowing of the width of the zone of entrainment as a predictor of the subsequent non-inducibility of reentrant ventricular tachycardia after an additional dose of an antiarrhythmic drug.
    Aizawa Y; Chinushi M; Naitoh N; Shibata A
    Heart; 1996 Feb; 75(2):165-70. PubMed ID: 8673755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of procainamide and quinidine for better tolerance and additive effects for ventricular arrhythmias.
    Kim SG; Seiden SW; Matos JA; Waspe LE; Fisher JD
    Am J Cardiol; 1985 Jul; 56(1):84-8. PubMed ID: 4014046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.